Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals

Neval Akbas, Patricia G. Schryver, Alicia Algeciras-Schimnich, Nikola A. Baumann, Darci R. Block, Jeffrey R. Budd, S. J Stephen Gaston, George G. Klee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). Methods: Clinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation; detection limits - 0.1 percentile of patient test values, linearity - 50% of total error, and consistency-percentage test values crossing key decision points. Local data were collected for precision, linearity, and consistency. Data were provided by Beckman Coulter, Inc. for trueness and detection limits. Results: All evaluated assays except total thyroxine were within the proposed goals for trueness. Most of the assays met the proposed goals for precision (86% of intra-assay results and 75% of inter-assay results). Five assays had more than 15% of the test results below the minimum detection limits. Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ±. 6.3%, ±. 5% and ±. 5.7% for dilution linearity. All evaluated assays were within the proposed goals for instrument consistency. Lot-to-lot consistency results for cortisol, ferritin and total thyroxine exceeded the proposed goals of 3.3%, 11.4% and 7% at one medical decision level, while vitamin B12 exceeded the proposed goals of 5.2% and 3.8% at two decision levels. Conclusions: The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.

Original languageEnglish (US)
Pages (from-to)158-163
Number of pages6
JournalClinical Biochemistry
Volume47
Issue number16-17
DOIs
StatePublished - Nov 1 2014

Fingerprint

Immunoassay
Limit of Detection
Assays
Thyroxine
Carcinoembryonic Antigen
Triiodothyronine
Vitamin B 12
Ferritins
Hydrocortisone
Dilution

Keywords

  • Analytical performance
  • Beckman Coulter DxI 800
  • Immunoassay
  • Precision
  • Quality control

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Akbas, N., Schryver, P. G., Algeciras-Schimnich, A., Baumann, N. A., Block, D. R., Budd, J. R., ... Klee, G. G. (2014). Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals. Clinical Biochemistry, 47(16-17), 158-163. https://doi.org/10.1016/j.clinbiochem.2014.08.005

Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals. / Akbas, Neval; Schryver, Patricia G.; Algeciras-Schimnich, Alicia; Baumann, Nikola A.; Block, Darci R.; Budd, Jeffrey R.; Gaston, S. J Stephen; Klee, George G.

In: Clinical Biochemistry, Vol. 47, No. 16-17, 01.11.2014, p. 158-163.

Research output: Contribution to journalArticle

Akbas, N, Schryver, PG, Algeciras-Schimnich, A, Baumann, NA, Block, DR, Budd, JR, Gaston, SJS & Klee, GG 2014, 'Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals', Clinical Biochemistry, vol. 47, no. 16-17, pp. 158-163. https://doi.org/10.1016/j.clinbiochem.2014.08.005
Akbas N, Schryver PG, Algeciras-Schimnich A, Baumann NA, Block DR, Budd JR et al. Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals. Clinical Biochemistry. 2014 Nov 1;47(16-17):158-163. https://doi.org/10.1016/j.clinbiochem.2014.08.005
Akbas, Neval ; Schryver, Patricia G. ; Algeciras-Schimnich, Alicia ; Baumann, Nikola A. ; Block, Darci R. ; Budd, Jeffrey R. ; Gaston, S. J Stephen ; Klee, George G. / Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals. In: Clinical Biochemistry. 2014 ; Vol. 47, No. 16-17. pp. 158-163.
@article{ce29d170098b4cc3ba480f0c4fa0cc63,
title = "Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals",
abstract = "Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). Methods: Clinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation; detection limits - 0.1 percentile of patient test values, linearity - 50{\%} of total error, and consistency-percentage test values crossing key decision points. Local data were collected for precision, linearity, and consistency. Data were provided by Beckman Coulter, Inc. for trueness and detection limits. Results: All evaluated assays except total thyroxine were within the proposed goals for trueness. Most of the assays met the proposed goals for precision (86{\%} of intra-assay results and 75{\%} of inter-assay results). Five assays had more than 15{\%} of the test results below the minimum detection limits. Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ±. 6.3{\%}, ±. 5{\%} and ±. 5.7{\%} for dilution linearity. All evaluated assays were within the proposed goals for instrument consistency. Lot-to-lot consistency results for cortisol, ferritin and total thyroxine exceeded the proposed goals of 3.3{\%}, 11.4{\%} and 7{\%} at one medical decision level, while vitamin B12 exceeded the proposed goals of 5.2{\%} and 3.8{\%} at two decision levels. Conclusions: The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.",
keywords = "Analytical performance, Beckman Coulter DxI 800, Immunoassay, Precision, Quality control",
author = "Neval Akbas and Schryver, {Patricia G.} and Alicia Algeciras-Schimnich and Baumann, {Nikola A.} and Block, {Darci R.} and Budd, {Jeffrey R.} and Gaston, {S. J Stephen} and Klee, {George G.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.clinbiochem.2014.08.005",
language = "English (US)",
volume = "47",
pages = "158--163",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "16-17",

}

TY - JOUR

T1 - Evaluation of Beckman Coulter DxI 800 immunoassay system using clinically oriented performance goals

AU - Akbas, Neval

AU - Schryver, Patricia G.

AU - Algeciras-Schimnich, Alicia

AU - Baumann, Nikola A.

AU - Block, Darci R.

AU - Budd, Jeffrey R.

AU - Gaston, S. J Stephen

AU - Klee, George G.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). Methods: Clinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation; detection limits - 0.1 percentile of patient test values, linearity - 50% of total error, and consistency-percentage test values crossing key decision points. Local data were collected for precision, linearity, and consistency. Data were provided by Beckman Coulter, Inc. for trueness and detection limits. Results: All evaluated assays except total thyroxine were within the proposed goals for trueness. Most of the assays met the proposed goals for precision (86% of intra-assay results and 75% of inter-assay results). Five assays had more than 15% of the test results below the minimum detection limits. Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ±. 6.3%, ±. 5% and ±. 5.7% for dilution linearity. All evaluated assays were within the proposed goals for instrument consistency. Lot-to-lot consistency results for cortisol, ferritin and total thyroxine exceeded the proposed goals of 3.3%, 11.4% and 7% at one medical decision level, while vitamin B12 exceeded the proposed goals of 5.2% and 3.8% at two decision levels. Conclusions: The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.

AB - Objectives: We evaluated the analytical performance of 24 immunoassays using the Beckman Coulter DxI 800 immunoassay systems at Mayo Clinic, Rochester, MN for trueness, precision, detection limits, linearity, and consistency (across instruments and reagent lots). Methods: Clinically oriented performance goals were defined using the following methods: trueness-published desirable accuracy limits, precision-published desirable biologic variation; detection limits - 0.1 percentile of patient test values, linearity - 50% of total error, and consistency-percentage test values crossing key decision points. Local data were collected for precision, linearity, and consistency. Data were provided by Beckman Coulter, Inc. for trueness and detection limits. Results: All evaluated assays except total thyroxine were within the proposed goals for trueness. Most of the assays met the proposed goals for precision (86% of intra-assay results and 75% of inter-assay results). Five assays had more than 15% of the test results below the minimum detection limits. Carcinoembryonic antigen, total thyroxine and free triiodothyronine exceeded the proposed goals of ±. 6.3%, ±. 5% and ±. 5.7% for dilution linearity. All evaluated assays were within the proposed goals for instrument consistency. Lot-to-lot consistency results for cortisol, ferritin and total thyroxine exceeded the proposed goals of 3.3%, 11.4% and 7% at one medical decision level, while vitamin B12 exceeded the proposed goals of 5.2% and 3.8% at two decision levels. Conclusions: The Beckman Coulter DxI 800 immunoassay system meets most of these proposed goals, even though these clinically focused performance goals represent relatively stringent limits.

KW - Analytical performance

KW - Beckman Coulter DxI 800

KW - Immunoassay

KW - Precision

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=84908658572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908658572&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2014.08.005

DO - 10.1016/j.clinbiochem.2014.08.005

M3 - Article

C2 - 25130957

AN - SCOPUS:84908658572

VL - 47

SP - 158

EP - 163

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 16-17

ER -